Antitumor and Immunoregulatory Activities of Seleno-β-Lactoglobulin on S180 Tumor-Bearing Mice

Degeneration of immune organs like thymus and spleen has been discovered in tumor-bearing mice; which increases the difficulties on oncotherapy. More effective drugs which target the protection of immune organs are expected to be researched. In this study; we aim to analyze the antitumor and immunoregulatory activities of seleno-β-lactoglobulin (Se-β-lg) on S180 tumor-bearing mice. Results indicated that Se-β-lg exhibited a remarkable inhibitory effect on S180 solid tumors with the inhibition rate of 48.38%; and protected the thymuses and spleens of S180-bearing mice. In addition, Se-β-lg could also balance the proportions of CD4(+) and CD8(+) T cells in spleens; thymuses and peripheral bloods; and improve Levels of IL-2; IFN-γ; TNF-α in mice serums. β-lg showed weaker bioactivities while SeO(2) showed stronger toxicity on mice. Therefore our results demonstrated that Se-β-lg possessed stronger antitumor and immunoregulatory activities with lower side effects and had the potential to be a novel immunopotentiator and antitumor agent.